Monitoring Progress and Adjusting Treatment Regular follow-ups with your healthcare provider are key
If symptoms are frequent or dangerous, the medicine may need to be stopped or the dose adjusted
Products marketed as research chemicals, compounded versions, or peptides may carry quality, dosing, sterility, and legal risks
According to section 1833(t)(3)(C)(iv) of the Act, the OPD fee schedule increase factor for a year must be equal to the IPPS market basket percentage increase factor applicable under section 1886(b)(3)(B)(iii) of the Act to hospital discharges in the fiscal year ending in such year
The two treatments differ significantly in how they work, their strength, their cost, and their side effects
Compared with placebo, there was higher use in the exenatide group of the SGLT-2 inhibitor dapagliflozin